Pioglitazone as a modulator of the chemoresistance of renal cell adenocarcinoma to methotrexate.

Pioglitazone as a modulator of the chemoresistance of renal cell adenocarcinoma to methotrexate. Oncol Rep. 2020 Jan 29;: Authors: Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Natorska-Chomicka D, Herbet M, Sysa M, Iwan M, Korga A, Dudka J Abstract Kidney cancer is one of the most lethal urological malignancies associated with a high risk of mortality. Recent studies have shown that several antidiabetic drugs may limit the risk of the growth of different types of cancer. Pioglitazone (PIO) belongs to a novel class of antidiabetic drugs called thiazolidinediones (TZDs), which are commonly used in the treatment of type 2 diabetes. This drug has been demonstrated to exert an inhibitory effect on cell growth in colon, prostatic, breast and pancreatic cancer lines. The aim of the present study was to assess the inhibitory effect of PIO on the proliferation of the renal adenocarcinoma cell line 769‑P. In addition, the proapoptotic potential of combined treatment with PIO and methotrexate (MTX) was evaluated, as well as the impact of the above drugs on the cell cycle of the 769‑P cells. The present study showed that PIO efficaciously inhibited the proliferation and viability of renal cancer cells, and it induced sub‑G1 cell cycle arrest and a decrease in the number of cells in the G2 phase, which indicated cytotoxic activity. PIO also exhibited proapoptotic properties at the lowest dose applied (10 µM). Furthermore, combined the...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research